|
ATE385421T1
(de)
†
|
2000-01-21 |
2008-02-15 |
Novartis Pharma Gmbh |
Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica
|
|
CN100348189C
(zh)
*
|
2002-12-10 |
2007-11-14 |
诺瓦提斯公司 |
DPP-IV抑制剂与PPAR-α化合物的组合
|
|
DE10300099A1
(de)
*
|
2003-01-07 |
2004-07-15 |
Bayer Healthcare Ag |
Indol-Phenylsulfonamid-Derivate
|
|
DE10308351A1
(de)
|
2003-02-27 |
2004-11-25 |
Aventis Pharma Deutschland Gmbh |
1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
|
AR044399A1
(es)
|
2003-05-20 |
2005-09-14 |
Novartis Ag |
Compuestos heterociclicos y su uso como activadores de receptores de ppar. composiciones farmaceuticas que los contienen
|
|
CA2531418A1
(en)
*
|
2003-07-08 |
2005-01-20 |
Novartis Ag |
Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds
|
|
DE10335449A1
(de)
*
|
2003-08-02 |
2005-02-17 |
Bayer Healthcare Ag |
Bicyclische Indolinsulfonamid-Derivate
|
|
US20080125403A1
(en)
|
2004-04-02 |
2008-05-29 |
Merck & Co., Inc. |
Method of Treating Men with Metabolic and Anthropometric Disorders
|
|
FR2869904B1
(fr)
*
|
2004-05-07 |
2006-07-28 |
Fournier S A Sa Lab |
Modulateurs des recepteurs lxr
|
|
GT200500246A
(es)
*
|
2004-09-09 |
2006-04-17 |
|
Combinacion de compuestos organicos
|
|
RU2007131501A
(ru)
*
|
2005-01-18 |
2009-02-27 |
Новартис АГ (CH) |
Способы применения двойных агонистов ppar и устройств для доставки лекарственных средств, содержащих такие соединения
|
|
US7429667B2
(en)
|
2005-01-20 |
2008-09-30 |
Ardea Biosciences, Inc. |
Phenylamino isothiazole carboxamidines as MEK inhibitors
|
|
FR2886293B1
(fr)
|
2005-05-30 |
2007-08-24 |
Fournier S A Sa Lab |
Nouveaux composes de l'indoline
|
|
ES2382876T3
(es)
|
2005-05-31 |
2012-06-14 |
Pfizer, Inc. |
Compuestos de ariloxi-N-biciclometil-acetamida sustituidos como antagonistas de VR1
|
|
WO2007008541A2
(en)
*
|
2005-07-08 |
2007-01-18 |
Kalypsys, Inc. |
Cellular cholesterol absorption modifiers
|
|
GT200600302A
(es)
*
|
2005-07-13 |
2007-03-19 |
|
Agonistas de ppara/y y procesos de preparación
|
|
PE20070335A1
(es)
|
2005-08-30 |
2007-04-21 |
Novartis Ag |
Benzimidazoles sustituidos y metodos para su preparacion
|
|
RU2008122547A
(ru)
*
|
2005-11-07 |
2009-12-20 |
Айрм Ллк (Bm) |
Соединения и композиции как модуляторы арпп (активированных рецепторов пролифератора пероксисом)
|
|
GB0526257D0
(en)
*
|
2005-12-22 |
2006-02-01 |
Novartis Ag |
Organic compounds
|
|
PT2402319T
(pt)
|
2006-03-31 |
2017-12-11 |
Novartis Ag |
Inibidores de dgat
|
|
US7842836B2
(en)
|
2006-04-11 |
2010-11-30 |
Ardea Biosciences |
N-aryl-N'alkyl sulfamides as MEK inhibitors
|
|
BRPI0709961A2
(pt)
|
2006-04-11 |
2011-08-02 |
Novartis Ag |
compostos orgánicos
|
|
AU2007237901B2
(en)
|
2006-04-18 |
2012-07-05 |
Ardea Biosciences, Inc. |
Pyridone sulfonamides and pyridone sulfamides as MEK inhibitors
|
|
PE20080888A1
(es)
|
2006-10-18 |
2008-08-26 |
Novartis Ag |
COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE LA ACIL-TRANSFERASA DE ACIL-CoA-DIACIL-GLICEROL 1 (DGAT1)
|
|
WO2008151257A2
(en)
|
2007-06-04 |
2008-12-11 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
|
CA2694646C
(en)
|
2007-07-30 |
2017-09-05 |
Ardea Biosciences, Inc. |
Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
|
|
ES2499018T3
(es)
|
2007-09-20 |
2014-09-26 |
Irm Llc |
Compuestos y composiciones como moduladores de la actividad de GPR119
|
|
US8736138B2
(en)
|
2007-09-28 |
2014-05-27 |
Brigham Young University |
Carbon nanotube MEMS assembly
|
|
US9305735B2
(en)
|
2007-09-28 |
2016-04-05 |
Brigham Young University |
Reinforced polymer x-ray window
|
|
US8498381B2
(en)
|
2010-10-07 |
2013-07-30 |
Moxtek, Inc. |
Polymer layer on X-ray window
|
|
ES2627848T3
(es)
|
2008-06-04 |
2017-07-31 |
Synergy Pharmaceuticals Inc. |
Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
|
|
EP2349484A2
(en)
|
2008-07-15 |
2011-08-03 |
Novartis AG |
Heteroaryl derivatives as dgat1 inhibitors
|
|
ES2624828T3
(es)
|
2008-07-16 |
2017-07-17 |
Synergy Pharmaceuticals Inc. |
Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
|
|
US8247971B1
(en)
|
2009-03-19 |
2012-08-21 |
Moxtek, Inc. |
Resistively heated small planar filament
|
|
US8673919B2
(en)
|
2009-03-27 |
2014-03-18 |
Ardea Biosciences, Inc. |
Dihydropyridin sulfonamides and dihydropyridin sulfamides as MEK inhibitors
|
|
CA2759187A1
(en)
*
|
2009-04-03 |
2010-10-07 |
Medisyn Technologies, Inc. |
Compositions for treatment of alzheimer's disease
|
|
WO2011014520A2
(en)
|
2009-07-29 |
2011-02-03 |
Irm Llc |
Compounds and compositions as modulators of gpr119 activity
|
|
CA2774573A1
(en)
|
2009-10-09 |
2011-04-14 |
Irm Llc |
Compounds and compositions as modulators of gpr119 activity
|
|
EP2947073B1
(en)
*
|
2009-10-22 |
2019-04-03 |
Fibrotech Therapeutics Pty Ltd |
Fused ring analogues of anti-fibrotic agents
|
|
US8394858B2
(en)
|
2009-12-03 |
2013-03-12 |
Novartis Ag |
Cyclohexane derivatives and uses thereof
|
|
US7983394B2
(en)
|
2009-12-17 |
2011-07-19 |
Moxtek, Inc. |
Multiple wavelength X-ray source
|
|
US8697739B2
(en)
|
2010-07-29 |
2014-04-15 |
Novartis Ag |
Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
|
|
WO2012027331A1
(en)
|
2010-08-27 |
2012-03-01 |
Ironwood Pharmaceuticals, Inc. |
Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
|
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
|
US8526574B2
(en)
|
2010-09-24 |
2013-09-03 |
Moxtek, Inc. |
Capacitor AC power coupling across high DC voltage differential
|
|
ES2618426T3
(es)
|
2010-10-07 |
2017-06-21 |
Novartis Ag |
Nuevas formas cristalinas de la sal sódica de ácido (4-{4-[5-(6-trifluorometil-piridin-3-ilamino)-piridin-2-il]-fenil}-ciclohexil)-acético
|
|
KR101569260B1
(ko)
|
2011-01-13 |
2015-11-13 |
노파르티스 아게 |
신규 헤테로시클릭 유도체 및 신경계 장애의 치료에서의 그의 용도
|
|
EA201391033A1
(ru)
|
2011-01-13 |
2014-01-30 |
Новартис Аг |
Ингибиторы bace-2 для лечения метаболических расстройств
|
|
US8804910B1
(en)
|
2011-01-24 |
2014-08-12 |
Moxtek, Inc. |
Reduced power consumption X-ray source
|
|
US8750458B1
(en)
|
2011-02-17 |
2014-06-10 |
Moxtek, Inc. |
Cold electron number amplifier
|
|
US8929515B2
(en)
|
2011-02-23 |
2015-01-06 |
Moxtek, Inc. |
Multiple-size support for X-ray window
|
|
US8792619B2
(en)
|
2011-03-30 |
2014-07-29 |
Moxtek, Inc. |
X-ray tube with semiconductor coating
|
|
US8614195B2
(en)
|
2011-04-14 |
2013-12-24 |
Novartis Ag |
Glycoside derivatives and uses thereof
|
|
JP2014510782A
(ja)
|
2011-04-14 |
2014-05-01 |
ノバルティス アーゲー |
グリコシド誘導体およびその使用
|
|
US8989354B2
(en)
|
2011-05-16 |
2015-03-24 |
Brigham Young University |
Carbon composite support structure
|
|
US9174412B2
(en)
|
2011-05-16 |
2015-11-03 |
Brigham Young University |
High strength carbon fiber composite wafers for microfabrication
|
|
US9076628B2
(en)
|
2011-05-16 |
2015-07-07 |
Brigham Young University |
Variable radius taper x-ray window support structure
|
|
EA201490228A1
(ru)
|
2011-07-08 |
2014-08-29 |
Новартис Аг |
Новые производные трифторметилоксадиазола и их применение для лечения заболевания
|
|
UY34278A
(es)
|
2011-08-25 |
2013-04-05 |
Novartis Ag |
Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
|
|
US9187439B2
(en)
|
2011-09-21 |
2015-11-17 |
Inception Orion, Inc. |
Tricyclic compounds useful as neurogenic and neuroprotective agents
|
|
US9284284B2
(en)
|
2011-10-13 |
2016-03-15 |
Novartis Ag |
Oxazine derivatives and their use in the treatment of disease
|
|
CA2856334A1
(en)
|
2011-11-28 |
2013-06-06 |
Christina Hebach |
Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease
|
|
US20150004144A1
(en)
|
2011-12-02 |
2015-01-01 |
The General Hospital Corporation |
Differentiation into brown adipocytes
|
|
US8761344B2
(en)
|
2011-12-29 |
2014-06-24 |
Moxtek, Inc. |
Small x-ray tube with electron beam control optics
|
|
WO2013163508A1
(en)
|
2012-04-27 |
2013-10-31 |
Novartis Ag |
Tetrahydropyran dgat1 inhibitors
|
|
MA37439B1
(fr)
|
2012-04-27 |
2017-02-28 |
Novartis Ag |
Inhibiteurs de dgat1 à ponts éthers cycliques pour le traitement de troubles medies par l'acyle coa-diacylglycerol transferase 1 (dgat1).
|
|
WO2014052619A1
(en)
|
2012-09-27 |
2014-04-03 |
Irm Llc |
Piperidine derivatives and compositions as modulators of gpr119 activity
|
|
CN104995188B
(zh)
|
2013-01-11 |
2018-09-14 |
诺华股份有限公司 |
2-((1r,4r)-4-(4-(5-(苯并噁唑-2-基氨基)吡啶-2-基)苯基)环己基)乙酸的葡甲胺盐形式和它们作为dgat1抑制剂的用途
|
|
US9173623B2
(en)
|
2013-04-19 |
2015-11-03 |
Samuel Soonho Lee |
X-ray tube and receiver inside mouth
|
|
PL3004138T3
(pl)
|
2013-06-05 |
2024-07-29 |
Bausch Health Ireland Limited |
Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie
|
|
US10588980B2
(en)
|
2014-06-23 |
2020-03-17 |
Novartis Ag |
Fatty acids and their use in conjugation to biomolecules
|
|
EP3157947A1
(en)
|
2014-06-23 |
2017-04-26 |
Novartis AG |
Hsa-gdf-15 fusion polypeptide and use thereof
|
|
US20190000923A1
(en)
|
2015-12-22 |
2019-01-03 |
Novartis Ag |
Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
|
|
EP3437651A1
(en)
|
2017-08-03 |
2019-02-06 |
Université de Strasbourg |
Peptides for treatment and prevention of nonalcoholic fatty liver disease
|
|
LT3723782T
(lt)
|
2017-12-14 |
2026-02-10 |
Université De Strasbourg |
Peptidai, skirti nealkoholinės kepenų suriebėjimo ligos gydymui ir profilaktikai
|
|
UY38485A
(es)
|
2018-11-27 |
2020-06-30 |
Novartis Ag |
Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
|
|
JP7657151B2
(ja)
|
2018-11-27 |
2025-04-04 |
ノバルティス アーゲー |
代謝性障害の処置のためのプロタンパク質コンバターゼスブチリシン/ケキシン9型(pcsk9)阻害剤としての環状ペプチド
|
|
WO2020110008A1
(en)
|
2018-11-27 |
2020-06-04 |
Novartis Ag |
Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder
|
|
RS64265B1
(sr)
|
2018-12-21 |
2023-07-31 |
Univ Strasbourg |
Peptidi za lečenje i prevenciju dijabetesa i povezanih poremećaja
|
|
WO2022219495A1
(en)
|
2021-04-12 |
2022-10-20 |
Novartis Ag |
2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
|
|
WO2023084449A1
(en)
|
2021-11-12 |
2023-05-19 |
Novartis Ag |
Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder
|
|
JP2025505198A
(ja)
|
2022-02-10 |
2025-02-21 |
ノバルティス アーゲー |
肥満の治療のためのglp1受容体の活性化因子としての2-((4-((s)-2-(4-クロロ-2-フルオロフェニル)-2-メチルベンゾ[d][1,3]ジオキソール-4-イル)ピペリジン-1-イル)メチル)-1-(((s)-オキセタン-2-イル)メチル)-1h-イミダゾール誘導体
|